ORIGINAL RESEARCH article
Front. Med.
Sec. Obstetrics and Gynecology
Volume 12 - 2025 | doi: 10.3389/fmed.2025.1581661
Effects of Dienogest Treatment on Endometrioma-related Clinical Symptoms and Endometrioma Size: Retrospective Cohort Study
Provisionally accepted
- 1Merkezefendi Hospital, Manisa, Türkiye
- 2Faculty of Medicine, Dokuz Eylül University, Izmir, Türkiye
- 3Seyfi Demirsoy State Hospital, Buca, Türkiye
- 4Faculty of Medicine, Tınaztepe University, Izmir, Türkiye
- 5Faculty of Medicine, Izmir Democracy University, İzmir, İzmir, Türkiye
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: To evaluate the efficacy and long-term safety of treatment with dienogest in patients with endometrioma.Methods: Patients with endometrioma-related chronic pelvic pain were included in this retrospective study from March 2018 to March 2023. Enrolled patients received 2 mg of dienogest once daily. Data from 180 patients were analyzed. Group 2 (n=104, 57.8%), comprising patients undergoing long-term therapy (>12 months), was compared with group 1 (n=76, 42.2%), consisting of patients undergoing short-term therapy (<2 months), regarding their response to changes in endometrioma size and visual analog scale (VAS) scores. Statistical analysis was performed using the SPSS version 26.0 software. Non-normally distributed parameters were analyzed using the Mann-Whitney U test. In the evaluation of the data, apart from identifying statistical methods, the t-test was used in comparison of paired groups, and the matched t-test was used in the determination of changes before and after treatment. The Chisquare test and Fisher's precision test were used in the analysis of categorical data. Categorical variables are presents as percentages, and quantitative variables are summarized as mean (95% confidence intervals) and median (minimum-maximum). P-values of <0.05 were considered statistically significant.Results: Findings at T0 (baseline) and T1 (sixth month) visits, in which the entire study cohort could be included, were compared. Then, patients who continued treatment at visits every 6 months after T1 (>12 months) were compared one by one with the findings at T0. The reduced libido was 4.3 times higher in the long-term group, but the weight gain was higher in the shortterm group. Analysis within all patients and individual groups (short term vs. long term) showed a significant decrease in endometrioma size and VAS scores between T0 and T1 visit findings.Similarly, the findings of T2 and each subsequent visit of the patients in the long-term group
Keywords: Ufuk Atlihan, MD Address: Merkezefendi, Mimar Sinan Street, Number:141/A, 45120 Merkez/Manisa/Turkey Ataturk, Hoca Ahmet Yesevi Street. Number: 27, 35390 Buca/Izmir/Turkey Manavkuyu, 250 Street
Received: 22 Feb 2025; Accepted: 17 Apr 2025.
Copyright: © 2025 Atlihan, Yavuz, ATA, Avsar and Erkilinc. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: CAN ATA, Seyfi Demirsoy State Hospital, Buca, Türkiye
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.